You are here

Home » Content

HP ERADİKASYONU VE ÜLSER İYİLEŞMESİNDE RANİTİDİN-BİZMUT SİTRAT İLE RANİTİDİN ARASINDA ANLAMLI FARK VAR MIDIR

Is There any Important Difference Between Ranitidine Bismuth Citrate and Ranitidine at Helicobacter Pylori Eradication and Ulcer Healing "

Journal Name:

  • İnönü Üniversitesi Tıp Fakültesi Dergisi

Publication Year:

  • 2000

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Fifty-six patients admitted to Inonu University Gastroenterology Department and detected duodenal or gastric ulcer in their endoscopies with Helicobacter pylori positivity in their endoscopic biopsies included in the study. The mean age of the patients was 37. Patients were divided in to two groups. Of 30 patients in the first group were given ranitidine bismuth citrate (RBC), 400 mg twice daily for one month, plus clarithromycin, 500 mg twice daily for one week, and amoxicillin, 1 gr twice daily for one week. Of 26 patients in the second group were given ranitidine, 300 mg twice daily for one month, plus clarithromycin, 500 mg twice daily for one week, and amoxicillin, 1 gr twice daily for one week. Endoscopic biopsies were repeated two weeks later at the end of the therapy and it was accepted as H. Pylori eradicated in negative biopsies. The Hpylori eradication rate was 100 % (24/24) in the first group and 69.5 % (16/23) in the second group with statistically significant difference. Ulcer healing rate was 100 % (24/24) in the first group and 86.9 % (20/23) in the second group with statistically significant difference. Both two regimens were well tolerated.
Bookmark/Search this post with
Abstract (Original Language): 
İnönü Üniversitesi Gastroenteroloji kliniğine başvuran ve yapılan endoskopilerinde duodenal yada gastrik ülser tespit edilen ve endoskopik biyopsilerinde Hp (+) bulunan yaş ortalaması 37 olan 56 hasta rastgele iki guruba ayrılarak birinci guruptaki 30 hastaya 1 ay süre RBS 2 x 400 mg/gün + 1 hafta Klaritromisin 2 x 500 mg/gün + lhafta 2x1 gr Amoksisilin verildi. İkinci guruptaki 26 hastaya ise 1 hafta Klaritromisin 2 x 500 mg/gün + Amoksisilin 2 xl gr/gün + 1 ay Ranitidin 2 x 300 mg/gün verildi. Tedavi bitiminden 2 hafta sonra tüm olgularda endoskopik biyopsi tekrarlandı ve Hp (-) olanlarda eradikasyon sağlandığı kabul edildi. Birinci guruptaki olgularda 6 hafta sonunda Hp eradikasyon oranı % 100 (24/24), ikinci grupta % 69.5 (16/23) idi ve iki gurup arasındaki fark istatistiksel olarak anlamlı idi. Ülser iyileşme oranları ise birinci gurupta %100 (24/24), ikinci gurupta ise % 86.9 (20/23) idi ve bu fark da istatistiksel olarak anlamlı bulundu (p<0.05).
FULL TEXT (PDF): 
PDF icon arastirmax-hp-eradikasyonu-ulser-iyilesmesinde-ranitidin-bizmut-sitrat-ile-ranitidin-arasinda-anlamli-fark-var-midir.pdf
  • 4
307-313
  • Turkish

REFERENCES

References: 

1. Graham DY, Breiter JR, Ciociola AA, Sykes DL, McSorley DJ. H. Pylori Study Group. An alternative non-macrolide, non-imidazole treatment regimen for curing Helicobacter pylori and duodenal ulcers: Ranidine Bismuth Citrate plus Amoxicillin. Helicobacter; 1998; 3(2): 12531.
2. Lind T, Veldhuyzen van Zanten SJO, Unge P, et al. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: The MACH I Study. Hecobacter 1996; 1: 38-44.
3. Laine L, Estrada R, Trujillo M, et al. Randomized comparison of differing periods twice-a-day therapy for the eradication of Helicobacter pylori. Aliment Pharmacol Ther, 1996; 10: 102933.
4. Laine L,Estrada R, Trujillo M, Sarvin E. Helicobacter pyloriye
yöneli
k Ranitidine Bizmut Sitrat Temelli Üçlü Tedavilerin Rastgele yöntemle Karşılaştırılması. Klinik Gastroenteroloji,1998;2: 103.
5. Bardhan KD, Wurzer H, Marcelino MJ, et al. High cur rates with ranitidine bismuth citrate (pylorid) plus claritromycin given twice daily.
Gut, 1996; 39(suppl 2): A36 (abstract).
6. Peterson WL, Ciociola AA, Sykes DL, et al. Ranitidine bismuth citrate plus claritromycin is effective for healing duodenal ulcers, eradicating H. Pylori and reducing ulcer reccurence. Aliment Pharmacol Ther, 1996;
10: 251-6.
7. Lanza F, Ciociola AA, Sykes DL, et al. Ranitidine bismuth citrate plus claritromycine is effective in eradicating H. Pylori, healing duodenal ulcer and preventing ulcer relaps. Gastroenterology 1996; 110: A 172 (abstract).
8. Wyeth JW, Pounder RF, Duggan AE, et al. The safety and efficacy of ranitidine bismuth citrate in combination with antibiotics for the eradication of Helicobacter pylori. Aliment Pharmacol Ther, 1996; 10:
623-30.
9. O'Riordan T, Mathai E, Tobin A et al. Adjuvant antibiotic therapy in duodenal ulcers treated with colloidal bismuth subcitrate. Gut, 1990; 31:
999-1002.
10.
Aydı
n A, Günşar F, Yılmaz M, Karasu Z, Özütemiz Ö, İlter T, Tunçyürek M. Helicobacter Pylori Eradikasyonunda Ranitidin Bizmut Sitraltı İkili ve Üçlü Tedaviler. Ulusal Gastroenteroloji Haftası, XIV. Ulusal Gastroenteroloji Kongre Kitapcığı; İstanbul, 1988; 54.
11. Tygat GNJ, Lee A, Graham DY, Dixon MF, Rokkas T. The role of infectios agents in peptic ulcer disease. Gastroenterol Internat, 1993; 6:
76-89.
12. Hentschel E, Brandstatter G, Dragosics B, et al. Effects of ranitidine and amoxicllin plus metranidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer. N Engl J Med, 1993; 328:
308-12.
13. Graham DY, Lew GM, Malaty HM, et all. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterol,
1992; 102: 486-93.
14. Eerupean Study Group on antibiotic susceptibility of helicobacter pylori. Results of a multicentre European Survey in 1991 ofmetranidazole resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis, 1992;
11: 777-81.
15. Glupczynski Y, Burrette A, De Koster E, Nyst J-F, Deltenre M, Cadranel S, Bourdeaux L, De Vos D. Metranidazole resistance in Helicobacter
pylori. Lancet, 1990; 335: 976-7.
16.
Kantarçeke
n B, Yıldırım B, Aladağ M, Karıncaoğlu M, F Hilmioğlu. Helicobacter Pylori ve antibiyotik direnci. Ulusal Gastroenteroloji haftası, XIV. Ulusal Gastroenteroloji Kongre kitapçığı, İstanbul, 1988; 1.
17. Brater DC, Peters MN, Eshelman FN, Richardson CT. Clinical comparison of cimetidine and ranitidine. Clin Pharmacol Ther, 1982; 32: 484-9.
18. Marshall BJ, Goodwin CS, Warren JR, et al. Prospective double blind trial of duodenal relapse after eradication of Campylobacter pylori.
Lancet, 1988; 2: 1437-42.
19. Carrick J. Problem with clinical trials on Campylobacter pylori. J Clin
Gastroenterol, 1988; 10: 247-8.
20. Bailey RJ, Marlicz K, Rosch W, et al. GR122311X (ranitidine bismuth
citrate), a new drug for the treatment of gastric ulcer (abstract).
Gastroenterol 1995; 108: A51.
21. McLaren A, McDowell SR, Bagshaw JA, et al. GR122311X and
clarithromycin against Helicobacter (abstract). Am J Gastroenterol,
1994; 89: 1382.
22. Lanza FL, Sontag SJ, Ciociola AA, et all. Ranitidine Bismuth Citrate Plus Claritromisin: A dual therapy regimen for patients with duodenal ulcer.
Helicobacter; 1998; 3(3): 212-21.
23. Peterson WL, Ciociola AA, Sykes DL, et al. Ranitidine bismuth citrate plus clarithromycin is effective for healing duodenal ulcer, eradicating H.pylori, and reducing ulcer recurrence. Aliment Pharmacol Ther, 1996;
10: 251-61.
24. Lancaster Smith MJ, Axon ATR, Ireland A. Ranitidine bismuth citrate in
combinatio
n with clarithromycin either 250 mg qds or 500 mg bd eradicates Helicobacter pylori in up to % 96 of patients with active duodenal ulcer disease (abstract). Gut, 1996; 39 (suppl 1): A 33 : T131.

Thank you for copying data from http://www.arastirmax.com